help button home button Am J Pathol International Conference on Pathology of Chest Diseases
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sousa, M. M.
Right arrow Articles by Saraiva, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sousa, M. M.
Right arrow Articles by Saraiva, M. J.
(American Journal of Pathology. 2002;161:1935-1948.)
© 2002 American Society for Investigative Pathology


Animal Model

Evidence for Early Cytotoxic Aggregates in Transgenic Mice for Human Transthyretin Leu55Pro

Mónica Mendes Sousa*, Rui Fernandes*, Joana Almeida Palha*, Ana Taboada*, Paulo Vieira{dagger} and Maria João Saraiva*{ddagger}

From the Amyloid Unit,* Instituto de Biologia Molecular e Celular, Porto; the Instituto Gulbenkian de Ciência,{dagger} Oeiras; and the Instituto de Ciências Biomédicas Abel Salazar,{ddagger} University of Porto, Porto, Portugal

Familial amyloidotic polyneuropathy (FAP) is a lethal autosomal dominant disorder characterized by systemic extracellular deposition of transthyretin (TTR) amyloid fibrils. Several groups have generated transgenic mice carrying human TTR Val30Met, the most common mutation in FAP. To study amyloidogenicity and cytotoxicity of different TTRs, we produced transgenic mice expressing human TTR Leu55Pro, one of the most aggressive FAP-related mutations. TTR deposition and presence of amyloid fibrils was investigated and compared to animals carrying the human TTR Val30Met gene kept under the same conditions. Deposition in a C57BL/6J background (TTR-Leu55Pro mice) and in a TTR-null background [TTR-Leu55Pro X TTR-knockout (KO) mice] was compared. Animals in a C57BL/6J background presented early (1 to 3 months) nonfibrillar TTR deposition but amyloid was absent. In a TTR-null background, presence of amyloid fibrils was detected starting at 4 to 8 months with a particular involvement of the gastrointestinal tract and skin. This data suggested that TTR homotetramers are more prone to fibril formation than TTR murine wild-type/human mutant heterotetramers. The nature of the deposited material was further investigated by immunocytochemistry. Both amorphous aggregates and small TTR fibrils were present in TTR-Leu55Pro X TTR-KO transgenics. We observed that these TTR deposits mimic the toxic effect of TTR deposits in FAP: animals with TTR deposition, present approximately twofold increased levels of nitrotyrosine in sites related to deposition. The TTR-Leu55Pro X TTR-KO mice here described are an important tool for the dual purpose of investigating factors involved in amyloidogenesis and in cytotoxicity of deposited TTR.





This article has been cited by other articles:


Home page
Protein Eng Des SelHome page
R. E. Steward, R. S. Armen, and V. Daggett
Different disease-causing mutations in transthyretin trigger the same conformational conversion
Protein Eng. Des. Sel., March 1, 2008; 21(3): 187 - 195.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. Reixach, T. R. Foss, E. Santelli, J. Pascual, J. W. Kelly, and J. N. Buxbaum
Human-Murine Transthyretin Heterotetramers Are Kinetically Stable and Non-amyloidogenic: A LESSON IN THE GENERATION OF TRANSGENIC MODELS OF DISEASES INVOLVING OLIGOMERIC PROTEINS
J. Biol. Chem., January 25, 2008; 283(4): 2098 - 2107.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
I. Cardoso and M. J. Saraiva
Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model
FASEB J, February 1, 2006; 20(2): 234 - 239.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
H. Koike, K. Misu, M. Sugiura, M. Iijima, K. Mori, M. Yamamoto, N. Hattori, E. Mukai, Y. Ando, S. Ikeda, et al.
Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy
Neurology, July 13, 2004; 63(1): 129 - 138.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. A. Liz, C. J. Faro, M. J. Saraiva, and M. M. Sousa
Transthyretin, a New Cryptic Protease
J. Biol. Chem., May 14, 2004; 279(20): 21431 - 21438.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
T. Korenaga, X. Fu, Y. Xing, T. Matsusita, K. Kuramoto, S. Syumiya, K. Hasegawa, H. Naiki, M. Ueno, T. Ishihara, et al.
Tissue Distribution, Biochemical Properties, and Transmission of Mouse Type A AApoAII Amyloid Fibrils
Am. J. Pathol., May 1, 2004; 164(5): 1597 - 1606.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
Y. Takaoka, M. Ohta, K. Miyakawa, O. Nakamura, M. Suzuki, K. Takahashi, K.-i. Yamamura, and Y. Sakaki
Cysteine 10 Is a Key Residue in Amyloidogenesis of Human Transthyretin Val30Met
Am. J. Pathol., January 1, 2004; 164(1): 337 - 345.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Society for Investigative Pathology.